Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.
Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.
Prediction: The Next Eli Lilly Might Already Be Trading Under $50 Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Should You Buy Viking Therapeutics Before Nov. 5? Viking's stock surged in one trading session after a positive clinical trial report last year.
3 Promising Growth Stocks That Are Down Around 60% From Their Highs These stocks may be down as of late, but investors shouldn't count them out in the long run.
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Why Is Viking Therapeutics Stock Rising Today? Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.
Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track.
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond These companies are jockeying for position in a potential $150 billion market opportunity.
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly? The smaller drugmaker is looking to disrupt a fast-growing market.
Down 44%, Should You Buy the Dip on Viking Therapeutics? The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
4 Healthcare Stocks to Buy Now As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
